COSMOS Pharmaceutical Corporation (3349.T)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Forecast and Price Target with Analyst Ratings, Revenue Estimates, and complete financial and advanced discounted cashflow forecasts for up to 10 years.

Trending:

COSMOS Pharmaceutical Corporation (3349.T) Stock Forecast & Price Prediction | Analyst Ratings

Revenue

964.99B

Higher than competitor

Better than 2127.T's revenue of 44.14B.

Revenue Growth Rate

16.59%

Higher than competitor

Better than 2127.T's revenue growth rate of 6.83%.

EBITDA

53.74B

Higher than competitor

Better than 2127.T's ebitda of 16.71B.

EBITDA Margin

5.57%

Lower than competitor

Worse than 2127.T's ebitda margin of 37.86%.

EBIT

33.82B

Higher than competitor

Better than 2127.T's ebit of 16.53B.

EBIT Margin

3.50%

Lower than competitor

Worse than 2127.T's ebit margin of 37.46%.

Depreciation

19.92B

Higher than competitor

Worse than 2127.T's depreciation of 174.71M.

Total Cash

52.30B

Higher than competitor

Better than 2127.T's total cash of 37.44B.

Cash as Percentage of Revenue

5.42%

Lower than competitor

Worse than 2127.T's cash as percentage of revenue of 84.83%.

Receivables

12.20B

Higher than competitor

Worse than 2127.T's receivables of 2.58B.

Receivables as Percentage of Revenue

1.26%

Lower than competitor

Better than 2127.T's receivables as percentage of revenue of 5.84%.

Inventories

86.17B

Higher than competitor

Worse than 2127.T's inventories of 0.00.

Inventories as Percentage of Revenue

8.93%

Higher than competitor

Worse than 2127.T's inventories as percentage of revenue of 0.00%.

Accounts Payable

179.55B

Higher than competitor

Worse than 2127.T's accounts payable of 924.04M.

Payables as Percentage of Revenue

18.61%

Higher than competitor

Worse than 2127.T's payables as percentage of revenue of 2.09%.

Capital Expenditure

-55.81B

Lower than competitor

Better than 2127.T's capital expenditure of -130.72M.

CapEx as Percentage of Revenue

-5.78%

Lower than competitor

Better than 2127.T's capex as percentage of revenue of -0.30%.

Weighted Average Cost of Capital (WACC)

5.08%

Lower than competitor

Better than 2127.T's weighted average cost of capital (wacc) of 6.72%.

Cost of Equity

5.18%

Lower than competitor

Better than 2127.T's cost of equity of 6.82%.

Cost of Debt

3.99%

Equal to 2127.T's cost of debt of 3.99%.

Beta

0.25

Lower than competitor

Better than 2127.T's beta of 0.60.

Diluted Shares Outstanding

79.24M

Lower than competitor

Better than 2127.T's diluted shares outstanding of 317.20M.

Total Debt

34.06B

Higher than competitor

Worse than 2127.T's total debt of 5.40B.

Total Equity

696.60B

Higher than competitor

Better than 2127.T's total equity of 221.09B.

Total Capital

730.66B

Higher than competitor

Better than 2127.T's total capital of 226.49B.

Debt Weighting

4.66%

Higher than competitor

Worse than 2127.T's debt weighting of 2.38%.

Equity Weighting

95.34%

Lower than competitor

Worse than 2127.T's equity weighting of 97.62%.

EBIAT

24.53B

Higher than competitor

Better than 2127.T's ebiat of 10.74B.

Unlevered Free Cash Flow

-14.10B

Lower than competitor

Worse than 2127.T's unlevered free cash flow of 11.72B.

Long-Term Growth Rate

2.00%

Equal to 2127.T's long-term growth rate of 2.00%.

Terminal Value

379.47B

Higher than competitor

Better than 2127.T's terminal value of 313.01B.

Enterprise Value

352.76B

Higher than competitor

Better than 2127.T's enterprise value of 279.06B.

Net Debt

-18.24B

Higher than competitor

Worse than 2127.T's net debt of -33.81B.

Equity Value

371.00B

Higher than competitor

Better than 2127.T's equity value of 312.87B.

Equity Value Per Share

4681.98

Higher than competitor

Better than 2127.T's equity value per share of 986.34.

Select Metric for Chart